Future of RNAi-Based Therapies for Human Papillomavirus-Associated Cervical Cancer

• Parkin DM , BrayF: Chapter 2: The burden of HPV-related cancers.Vaccine24(Suppl. 3), S11–S25 (2006).
   Web of Science ®Google Scholar
• Parkin DM : The global health burden of infection-associated cancers in the year 2002.Int. J. Cancer118, 3030–3044 (2006).
   PubMed Web of Science ®Google Scholar
• zur Hausen H : Papillomaviruses and cancer: from basic studies to clinical application.Nat. Rev. Cancer2, 342–350 (2002).
   PubMed Web of Science ®Google Scholar
• Hudelist G , ManaviM, PischingerKIet al.: Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol. Oncol.92, 873–880 (2004).
   PubMed Web of Science ®Google Scholar
• Goodwin EC , DiMaioD: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.Proc. Natl Acad. Sci. USA97, 12513–12518 (2000).
   PubMed Web of Science ®Google Scholar
• Munger K , WernessBA, DysonN, PhelpsWC, HarlowE, HowleyPM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J.8, 4099–4105 (1989).
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M , OltersdorfT, SchwarzE, GissmannL: Correlation of modified human papilloma virus early gene expression with altered growth properties in C4–1 cervical carcinoma cells.Cancer Res.48, 3780–3786 (1988).
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M , KiyonoT: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.Cancer Sci.98(10), 1505–1511 (2007).
   PubMed Web of Science ®Google Scholar
• Scheffner M , WhitakerNJ: Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system.Semin. Cancer Biol.13, 59–67 (2003).
   PubMed Web of Science ®Google Scholar
• Putral LN , BywaterMJ, GuWet al.: RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol. Pharmacol.68, 1311–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Gu W , PutralL, HengstKet al.: Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther.13, 1023–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Tang S , TaoM, McCoyJPJr, ZhengZM: The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol.80, 4249–4263 (2006).
   PubMed Web of Science ®Google Scholar
• Hamada K , ShirakawaT, GotohA, RothJA, FollenM: Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.Gynecol. Oncol.103, 820–830 (2006).
   PubMed Web of Science ®Google Scholar
• Choo CK , LingMT, SuenCK, ChanKW, KwongYL: Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells.Gynecol. Oncol.78, 293–301 (2000).
   PubMed Web of Science ®Google Scholar
• Lappalainen K , UrttiA, JaaskelainenI, SyrjanenK, SyrjanenS: Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells.Antiviral Res.23, 119–130 (1994).
   PubMed Web of Science ®Google Scholar
• Lappalainen K , PirilaL, JaaskelainenI, SyrjanenK, SyrjanenS: Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene.Anticancer Res.16, 2485–2492 (1996).
   PubMed Web of Science ®Google Scholar
• Alvarez-Salas LM , Benitez-HessML, DiPaoloJA: Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.Antivir. Ther.8, 265–278 (2003).
   PubMed Web of Science ®Google Scholar
• Chen Z , KamathP, ZhangS, WeilMM, ShillitoeEJ: Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18.Cancer Gene Ther.2, 263–271 (1995).
   PubMed Web of Science ®Google Scholar
• Chen Z , KamathP, ZhangS, St JohnL, Adler-StorthzK, ShillitoeEJ: Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther.3, 18–23 (1996).
   PubMed Web of Science ®Google Scholar
• Alvarez-Salas LM , CullinanAE, SiwkowskiA, HampelA, DiPaoloJA: Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl Acad. Sci. USA95, 1189–1194 (1998).
   PubMed Web of Science ®Google Scholar
• Hamada K , SakaueM, AlemanyRet al.: Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol.63, 219–227 (1996).
   PubMed Web of Science ®Google Scholar
• Bitko V , MusiyenkoA, ShulyayevaO, BarikS: Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med.11(1), 50-55 (2004).
   PubMed Web of Science ®Google Scholar
• Dasgupta R , PerrimonN: Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research.Oncogene23, 8359–8365 (2004).
   PubMed Web of Science ®Google Scholar
• Hannon GJ , RossiJJ: Unlocking the potential of the human genome with RNA interference.Nature431, 371–378 (2004).
   PubMed Web of Science ®Google Scholar
• Capodici J , KarikoK, WeissmanD: Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference.J. Immunol.169, 5196–5201 (2002).
   PubMed Web of Science ®Google Scholar
• Jacque JM , TriquesK, StevensonM: Modulation of HIV-1 replication by RNA interference.Nature418, 435–438 (2002).
   PubMed Web of Science ®Google Scholar
• Filipowicz W , JaskiewiczL, KolbFA, PillaiRS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin Struct. Biol.15, 331–341 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang M , MilnerJ: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.Oncogene21, 6041–6048 (2002).
   PubMed Web of Science ®Google Scholar
• Butz K , RistrianiT, HengstermannA, DenkC, ScheffnerM, Hoppe-SeylerF: siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene22, 5938–5945 (2003).
   PubMed Web of Science ®Google Scholar
• Hall AH , AlexanderKA: RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells.J. Virol.77, 6066–6069 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshinouchi M , YamadaT, KizakiMet al.: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther.8, 762–768 (2003).
   PubMed Web of Science ®Google Scholar
• Jiang M , MilnerJ: Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs.Methods Mol. Biol.292, 401–420 (2004).
   Google Scholar
• Schiffelers RM , AnsariA, XuJet al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res.32, E149 (2004).
   PubMed Web of Science ®Google Scholar
• Guo P : RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.J. Nanosci. Nanotechnol.5, 1964–1982 (2005).
   PubMed Web of Science ®Google Scholar
• Baigude H , McCarrollJ, YangCS, SwainPM, RanaTM: Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol.2, 237–241 (2007).
   PubMed Web of Science ®Google Scholar
• Thurston G , McLeanJW, RizenMet al.: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest.101, 1401–1413 (1998).
   PubMed Web of Science ®Google Scholar
• Nogawa M , YuasaT, KimuraSet al.: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest.115, 978–985 (2005).
   PubMed Web of Science ®Google Scholar
• Chien PY , WangJ, CarbonaroDet al.: Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo.Cancer Gene Ther.12, 321–328 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmermann TS , LeeAC, AkincAet al.: RNAi-mediated gene silencing in non-human primates. Nature441, 111–114 (2006).
   PubMed Web of Science ®Google Scholar
• Snove O Jr , RossiJJ: Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol.7, 231 (2006).
   PubMed Web of Science ®Google Scholar
• Barik S : RNAi in moderation.Nat. Biotechnol.24, 796–797 (2006).
   PubMed Web of Science ®Google Scholar
• Das AT , BrummelkampTR, WesterhoutEMet al.: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol.78, 2601–2605 (2004).
   PubMed Web of Science ®Google Scholar
• Tang S , TaoM, McCoyJPJr, ZhengZM: Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene25, 2094–2104 (2006).
   PubMed Web of Science ®Google Scholar
• Chen J , McMillanNA: Multiple signal pathways in the leukemogenesis and therapeutic implications.Leuk. Res. (2007). (Epub ahead of print).
   Web of Science ®Google Scholar
• Yu J , ZhangL: The transcriptional targets of p53 in apoptosis control.Biochem. Biophys. Res. Commun.331, 851–858 (2005).
   PubMed Web of Science ®Google Scholar
• Espinosa JM , VerdunRE, EmersonBM: p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage.Mol. Cell12, 1015–1027 (2003).
   PubMed Web of Science ®Google Scholar
• Braun K , EhemannV, WaldeckWet al.: HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs).Cancer Lett.209, 37–49 (2004).
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR , FabiusAW, MullendersJet al.: An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol.2, 202–206 (2006).
   PubMed Web of Science ®Google Scholar
• Huh JJ , WolfJK, FightmasterDL, LotanR, FollenM: Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells.Gynecol. Oncol.89, 243–250 (2003).
   PubMed Web of Science ®Google Scholar
• Suga S , KatoK, OhgamiTet al.: An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol. Oncol.105, 341–350 (2007).
   PubMed Web of Science ®Google Scholar
• Dyson N , HowleyPM, MungerK, HarlowE: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science243, 934–937 (1989).
   PubMed Web of Science ®Google Scholar
• Fiedler M , Muller-HolznerE, ViertlerHPet al.: High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J.18, 1120–1122 (2004).
   PubMed Web of Science ®Google Scholar
• Narita M , NunezS, HeardEet al.: Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell113, 703–716 (2003).
   PubMed Web of Science ®Google Scholar
• Nevins JR : E2F: a link between the Rb tumor suppressor protein and viral oncoproteins.Science258, 424–429 (1992).
   PubMed Web of Science ®Google Scholar
• Alonso MM , FueyoJ, YungWK, Gomez-ManzanoC: E2F1 and telomerase: alliance in the dark side.Cell Cycle5, 930–935 (2006).
   PubMed Web of Science ®Google Scholar
• Olson MV , JohnsonDG, JiangHet al.: Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res.67, 4005–4009 (2007).
   PubMed Web of Science ®Google Scholar
• Ha WY , WuPK, KokTWet al.: Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma. Int. J. Biochem. Cell Biol.38, 1393–1401 (2006).
   PubMed Web of Science ®Google Scholar
• Chellappan SP , HiebertS, MudryjM, HorowitzJM, NevinsJR: The E2F transcription factor is a cellular target for the Rb protein.Cell65, 1053–1061 (1991).
   PubMed Web of Science ®Google Scholar
• Matsushime H , EwenME, StromDKet al.: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell71, 323–334 (1992).
   PubMed Web of Science ®Google Scholar
• Ewen ME , SlussHK, SherrCJ, MatsushimeH, KatoJ, LivingstonDM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell73, 487–497 (1993).
   PubMed Web of Science ®Google Scholar
• Lau WM , HoTH, HuiKM: p16(INK4A)-silencing augments DNA damage-induced apoptosis in cervical cancer cells.Oncogene (2007).
   Web of Science ®Google Scholar
• Menges CW , BagliaLA, LapointR, McCanceDJ: Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res.66, 5555–5559 (2006).
   PubMed Web of Science ®Google Scholar
• Hagemann T , BozanovicT, HooperSet al.: Molecular profiling of cervical cancer progression. Br. J. Cancer96, 321–328 (2007).
   PubMed Web of Science ®Google Scholar
• Priulla M , CalastrettiA, BrunoPet al.: Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate67, 782–789 (2007).
   PubMed Web of Science ®Google Scholar
• Faried LS , FariedA, KanumaTet al.: Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur. J. Cancer42, 934–947 (2006).
   PubMed Web of Science ®Google Scholar
• Beuvink I , BoulayA, FumagalliSet al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell120, 747–759 (2005).
   PubMed Web of Science ®Google Scholar
• Iwamaru A , KondoY, IwadoEet al.: Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene26, 1840–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Nair A , VenkatramanM, MaliekalTT, NairB, KarunagaranD: NF-κB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene22, 50–58 (2003).
   PubMed Web of Science ®Google Scholar
• Prusty BK , HusainSA, DasBC: Constitutive activation of nuclear factor-κB: preferntial homodimerization of p50 subunits in cervical carcinoma.Front. Biosci.10, 1510–1519 (2005).
   PubMed Web of Science ®Google Scholar
• Hayden MS , GhoshS: Signaling to NF-κB.Genes Dev.18, 2195–2224 (2004).
   PubMed Web of Science ®Google Scholar
• An HJ , ChoNH, YangHSet al.: Targeted RNA interference of phosphatidylinositol 3-kinase p110-b induces apoptosis and proliferation arrest in endometrial carcinoma cells. J. Pathol.212, 161–169 (2007).
   PubMed Web of Science ®Google Scholar
• Catz SD , JohnsonJL: Transcriptional regulation of Bcl-2 by nuclear factor κB and its significance in prostate cancer.Oncogene20, 7342–7351 (2001).
   PubMed Web of Science ®Google Scholar
• Viatour P , Bentires-AljM, ChariotAet al.: NF- κB2/p100 induces Bcl-2 expression. Leukemia17, 1349–1356 (2003).
   PubMed Web of Science ®Google Scholar
• Dimitrakakis C , KymionisG, DiakomanolisEet al.: The possible role of p53 and Bcl-2 and expression in cervical carcinomas and their premalignant lesions. Gynecol. Oncol.77, 129–136 (2000).
   PubMed Web of Science ®Google Scholar
• Lei XY , ZhongM, FengLF, ZhuBY, TangSS, LiaoDF: siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin. Exp. Pharmacol. Physiol.34, 450–456 (2007).
   PubMed Web of Science ®Google Scholar
• Pandyra A , BergR, VincentM, KoropatnickJ: Combination siRNA targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. J. Pharmacol. Exp. Ther.322(1), 123–132 (2007).
   PubMed Web of Science ®Google Scholar
• Nagamatsu K , TsuchiyaF, OgumaK, MaruyamaH, KanoR, HasegawaA: The effect of small interfering RNA (siRNA) against the Bcl-2 gene on apoptosis and chemosensitivity in a canine mammary gland tumor cell line.Res. Vet. Sci. (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Zheng Y , ZhangJ, RaoZ: Ribozyme targeting HPV16 E6/E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy.Cancer Biol. Ther.3, 1129–1134; discussion 1135–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Wright TC , BoschFX, FrancoELet al.: Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine24(Suppl. 3) S251–S261 (2006).
   Web of Science ®Google Scholar

Website

• RNAi eNewsletter Vol. 7 issue 6 www.rnai.net
   Google Scholar